Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
beta-catenin
plays an important role in development and homeostasis. Deregulated
beta-catenin
is involved in oncogenesis. In this study, we found that
beta-catenin
can physically complex with NF-kappa B, resulting in a reduction of NF-kappa B DNA binding, transactivation activity, and target gene expression. Repressed NF-kappa B activity is found in human
colon cancer
cells in which
beta-catenin
is activated. Importantly, activated
beta-catenin
was found to inhibit the expression of NF-kappa B target genes, including Fas and TRAF1. Furthermore, a strong inverse correlation was identified between the expression levels of
beta-catenin
and Fas in colon and breast tumor tissues, suggesting that
beta-catenin
regulates NF-kappa B and its targets in vivo. Thus,
beta-catenin
may play an important role in oncogenesis through the crossregulation of NF-kappa B.
...
PMID:beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. 1239 96
Mutations in the adenomatous polyposis coli (APC) gene, which initiate almost all human colon cancers, directly target the proto-oncogene, c-myc, by elevating
beta-catenin
/T-cell factor (TCF) signaling. We have shown that agents ascribed chemopreventive activity for
colon cancer
in fact also stimulate
beta-catenin
/TCF activity in vitro. Their effects on c-myc transcription were assayed using a novel variant of fluorescence in situ hybridization that detects c-myc transcription sites in intact nuclei. Increased transcriptional initiation of c-myc induced by the short-chain fatty acid, butyrate, consistent with elevated
beta-catenin
/TCF activity, was efficiently abrogated by a block to transcriptional elongation, resulting in decreased c-myc expression. 1alpha,25-Dihydroxyvitamin D(3) also induced transcriptional blockage. In contrast, the nonsteroidal anti-inflammatory drug, sulindac, increased c-myc expression, an effect attributable at least in part to its failure to induce transcriptional blockage. We have described a novel approach for evaluating the effects of chemopreventive agents on the expression of a gene critical in colonic tumorigenesis.
...
PMID:Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. 1241 19
The adenomatous polyposis coli (APC) or
beta-catenin
genes are frequently mutated in colorectal cancers, leading to activation of downstream genes with
beta-catenin
/T-cell factor (Tcf)-responsive promoters. We have developed a gene therapy approach selectively targeting colorectal cancer cells in which
beta-catenin
/Tcf4 pathway is activated by using a recombinant adenovirus AdTOP-CMV-TK, which carries a herpes simplex virus thymidine kinase gene (HSV TK) under the control of a
beta-catenin
/Tcf-response promoter linking to a minimum CMV promoter. AdTOP-CMV-TK and ganciclovir (GCV) treatment significantly suppressed the growth of human DLD-1
colon cancer
cells in nude mice. Furthermore, no significant tumor suppression effect was observed in human hepatoma cell line SK-HEP-1, in which the
beta-catenin
/Tcf pathway is not activated, as a control experiment. In summary, we demonstrated the selective targeting of colorectal cancers with activated
beta-catenin
by AdTOP-CMV-TK and GCV treatment in animal models, as well as its therapeutic potential for
colon cancer
metastasized to liver.
...
PMID:The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. 1244 97
Infection of the gastrointestinal tract by the human polyomavirus, JCV, which has been frequently detected in raw urban sewage, can occur via intake of contaminated water and food. In light of earlier reports on the tumorigenecity of JCV, we investigated the presence of the JCV genome and the expression of viral proteins in a collection of 27 well-characterized epithelial malignant tumors of the large intestine. Results from gene amplification revealed the presence of the viral early genome in 22 of 27 samples. Expression of the viral oncogenic early protein, T-antigen, and the late auxiliary protein, Agnoprotein, was observed in >50% of the samples. The absence of the viral capsid protein in the tumor cells excludes productive replication of the virus in neoplastic cells. Laser capture microdissection confirmed the presence of the JCV genome and expression of T-antigen in precancerous villous adenomas and regions of invasive adenocarcinoma. The ability of JCV T-antigen to interact with
beta-catenin
and the nuclear detection of
beta-catenin
in T-antigen-positive cells suggests dysregulation of the Wnt pathway in the tumor cells. The coproduction of T-antigen and
beta-catenin
in
colon cancer
cells enhanced transcription of the c-myc promoter, the downstream target of
beta-catenin
. These observations provide evidence for a possible association of JCV with
colon cancer
and suggest a novel regulatory role for T-antigen in the deregulation of the Wnt signaling pathway through
beta-catenin
in tumors of the gastrointestinal tract.
...
PMID:Association of human polyomavirus JCV with colon cancer: evidence for interaction of viral T-antigen and beta-catenin. 1246 Sep 31
The development of nontoxic natural agents with chemopreventive activity against
colon cancer
is the focus of investigation in many laboratories. Curcumin (feruylmethane), a natural plant product, possesses such chemopreventive activity, but the mechanisms by which it prevents cancer growth are not well understood. In the present study, we examined the mechanisms by which curcumin treatment affects the growth of
colon cancer
cells in vitro. Results showed that curcumin treatment causes p53- and p21-independent G(2)/M phase arrest and apoptosis in HCT-116(p53(+/+)), HCT-116(p53(-/-)) and HCT-116(p21(-/-)) cell lines. We further investigated the association of the
beta-catenin
-mediated c-Myc expression and the cell-cell adhesion pathways in curcumin-induced G(2)/M arrest and apoptosis in HCT-116 cells. Results described a caspase-3-mediated cleavage of
beta-catenin
, decreased transactivation of
beta-catenin
/Tcf-Lef, decreased promoter DNA binding activity of the
beta-catenin
/Tcf-Lef complex, and decreased levels of c-Myc protein. These activities were linked with decreased Cdc2/cyclin B1 kinase activity, a function of the G(2)/M phase arrest. The decreased transactivation of
beta-catenin
in curcumin-treated HCT-116 cells was unpreventable by caspase-3 inhibitor Z-DEVD-fmk, even though the curcumin-induced cleavage of
beta-catenin
was blocked in Z-DEVD-fmk pretreated cells. The curcumin treatment also induced caspase-3-mediated degradation of cell-cell adhesion proteins
beta-catenin
, E-cadherin and APC, which were linked with apoptosis, and this degradation was prevented with the caspase-3 inhibitor. Our results suggest that curcumin treatment impairs both Wnt signaling and cell-cell adhesion pathways, resulting in G(2)/M phase arrest and apoptosis in HCT-116 cells.
...
PMID:Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. 1246 62
Activation of
beta-catenin
is a critical step in the pathogenesis of many common human cancers and is the initiating event in adenocarcinoma of the colon. Because activation of
beta-catenin
provides a gain-of-function, it is tempting to speculate that specific pharmacological inhibition of activated
beta-catenin
might reverse the tumorigenic properties of human cancer cells and therefore form the basis of an effective anticancer strategy. In an effort to provide proof-of-principle for such a strategy, we used a novel clonal growth assay based on human somatic cell gene targeting to determine whether activated
beta-catenin
remains a necessary oncogenic stimulus in advanced human cancer cells. Using this approach, we demonstrate that
beta-catenin
is a necessary oncogene in human SW48 and DLD1
colon cancer
cells but not in HCT116 cells. These data indicate that activated
beta-catenin
can remain a critical oncogenic stimulus throughout the progression of human
colon cancer
and suggest that the small molecule inhibitors of activated
beta-catenin
currently under development will be effective anticancer therapeutics in a subset of malignant colon cancers.
...
PMID:Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. 1251 70
Ca(2+) has chemopreventive activity against
colon cancer
, albeit its mechanisms of action are not understood. In this study, we showed that four different human colon carcinoma cell lines (FET, SW480, MOSER, and CBS) expressed the human parathyroid calcium sensing receptor (CaSR) and that a function of extracellular Ca(2+) and the CaSR in these cells was the promotion of E-cadherin expression and suppression of
beta-catenin
/T cell factor activation. We also found that human colonic crypt epithelial cells expressed the CaSR, and histologically differentiated carcinomas (i.e., where three-dimensional, crypt-like structures were present) expressed less receptor by comparison, whereas an almost complete loss of CaSR expression was observed in undifferentiated tumors. These results suggest that extracellular Ca(2+) and the CaSR may function to regulate the differentiation of colonic epithelial cells and that disruption of this ligand receptor system may contribute to abnormal differentiation and malignant progression. In addition, the promotion of E-cadherin and suppression of
beta-catenin
/T cell factor may be an important mechanism underlying the chemopreventive action of Ca(2+) in
colon cancer
.
...
PMID:Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. 1251 79
Radiotherapy for malignant pelvic disease is commonly accompanied by treatment-induced proctitis, and rarely by colorectal cancer. Translocation of the
beta-catenin
protein, which is a key downstream effector of the Wnt signal transduction pathway, is frequently found in colorectal cancer. Nuclear
beta-catenin
enhances transcriptional activity of the cyclin D1 gene in cancer cells. Here, we evaluate the involvement of the Wnt pathway in radiation-induced colon carcinogenesis with rats (n = 36).
Beta-catenin
, APC, and cyclin D1 expression profiles were analyzed by immunohistochemistry in radiation-induced chronic colon injury including cancers and ulcerative lesions in rats (n = 12 in treated group, n = 12 in control group). In total, 3 cases of invasive adenocarcinomas were developed in the irradiated portion 50 weeks after a single dose of 36 Gy irradiation. Nuclear translocation of
beta-catenin
was observed in all radiation-induced colon cancers, whereas this protein was also found in the cytoplasm and/or nucleus of 9 cases of non-neoplastic irradiated colonocytes. Nuclear translocation of
beta-catenin
correlated with loss of APC and gain of cyclin D1 expression, suggesting activation of the Wnt pathway during radiation-induced colorectal carcinogenesis. A single dose of 10 Gy was also given for acute injury (n = 12: 3 each in days 0, 3, 5, and 7, respectively).
Beta-catenin
expression was distributed in the cytoplasm of degenerating glands at day 3 and 5, and was observed in the cell membrane of those glands with histological normalization at day 7 after irradiation. Because translocation of
beta-catenin
was found in irradiated-colonic mucosa as well as
colon cancer
, disruption of
beta-catenin
expression might be one of the early events in radiation-induced colonic carcinogenesis.
...
PMID:Altered expression of beta-catenin during radiation-induced colonic carcinogenesis. 1253 May 73
We have previously identified SU(Z)12 as an E2F target gene. Because many E2F target genes encode proteins that are critical for the control of cell proliferation, we have further characterized the regulation and expression of SU(Z)12. To understand the molecular mechanisms responsible for expression of SU(Z)12 mRNA, we have analyzed the promoter region. We found that the SU(Z)12 gene is controlled by dual promoters, one of which functions bidirectionally. In addition to the E2F binding site, we have identified two binding sites for T cell factor (TCF)/
beta-catenin
complexes. Using gel mobility shift assays, we demonstrated that both TCF sites can be bound by TCF4. TCF/
beta-catenin
complexes have been shown to be a critical regulator of gene expression in tumors of the colon, breast, and liver. Accordingly, we have used chromatin immunoprecipitation assays to confirm that TCF4/
beta-catenin
complexes are bound to the SU(Z)12 promoter in
colon cancer
cells but not in HeLa cells. We next adapted the chromatin immunoprecipitation assay for use with primary colon tumor samples, and, using matched pairs of normal and tumor tissue obtained from several different
colon cancer
patients, we demonstrate that levels of
beta-catenin
bound to the SU(Z)12 promoter are increased in colon tumors. Finally, we show that the SU(Z)12 mRNA is up-regulated in a number of different human tumors, including tumors of the colon, breast, and liver. Recent studies have found that SU(Z)12 is a component of the Drosophila ESC-E(Z) and the human EED-EZH2 Polycomb chromatin remodeling complexes. Therefore, we suggest that SU(Z)12, which may modulate the tumor phenotype by changing gene expression profiles, may be a logical target for the design of a new antitumor agent
...
PMID:Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. 1253 79
Medulloblastoma is a malignant, invasive embryonal tumour of the cerebellum which manifests preferentially in children. A subset of cases is associated with
colon cancer
and APC germline mutations (Turcot syndrome), and APC and
beta-catenin
point mutations occur in up to 10% of sporadic cases, indicating the involvement of the Wnt pathway in the development of medulloblastoma. In 39 sporadic cerebellar medulloblastomas screeened for alterations in the AXIN1 gene, another component of the Wnt pathway, we found missense AXIN1 mutations in two tumours, CCC-->TCC at codon 255 (exon 1, Pro-->Ser) and TCT-->TGT at codon 263 (exon 1, Ser-->Cys). Furthermore, the A allele at the G/A polymorphism at nucleotide 16 in intron 4 was significantly over-represented in medulloblastomas (39 cases; G 0.76 vs-A 0.24) compared to healthy individuals (86 cases; G 0.91 vs A 0.09; P=0.0027). RT-PCR revealed large deletions in the AXIN1 gene in 5/12 (42%) medulloblastomas, consistent with a previous report. However, we observed such deletions at a similar frequency also in normal brain tissue (6/12, 50%). Since there are multiple complementary, inverted sequences present in the AXIN1 gene, these large deletions may represent RT-PCR errors due to stem-loop secondary structures.
...
PMID:AXIN1 mutations but not deletions in cerebellar medulloblastomas. 1255 76
<< Previous
1
2
3
4
5
6
7
8
9
10